Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: part 2

• Shuai Hao ; Guillermo E. Umpierrez ; Priyathama Vellanki ^[1]
  1. [1] Emory University

     Emory University

     Estados Unidos

     
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 1, 2023, págs. 39-47
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Newer agents, such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual incretin agonists, can augment β-cell function and delay the need for additional antihyperglycemics. However, the effect on β-cell function ceases after stopping the medications. When combined with intensive lifestyle modifications, higher doses of GLP-1RA than those used for diabetes treatment can be used to induce weight loss. More research is needed on whether the weight loss achieved with GLP1-RA can be sustained after stopping medication and in turn can sustain diabetes remission.